alexa
Reach Us +1-217-403-9671
BIOEQUIVALENCE IN TRANS DERMALS | 8333
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

BIOEQUIVALENCE IN TRANS DERMALS

International Conference & Exhibition Bioequivalence and Bioavailability

Charu Gautam

ScientificTracks Abstracts: J Bioequiv Availab 2010

DOI: 10.4172/0975-0851.1000001

Abstract
T ransdermal drug delivery system has been in existence for a long time. In the past, the most commonly applied systems were topically applied creams and ointments for dermatological disorders. Now there are novel patches in various therapeutic areas. The Transdermal Drug Delivery System (TDDS) offers several advantages over the traditional orals and injectables. It is a controlled release of drug, does not require frequent dose, is painless and most importantly does not undergo first pass metabolism. With such advantages, the Pharmaceutical industry is developing several TDDS for drugs used in elderly, children, chronic illness etc. Bioavalability with transdermals poses certain challenges such as variability, physicological differences and formulation differences. The patches also pose problems such as skin sensitization and irritability. One of the important aspect is adhesivity of the patch. Considering the various factors affecting the bioavailability of transdermals, the regualtory has defined certain guidelines for the conduct of such studies. The bioequivalence of a TDDS in comparison to the innovator's product should usually be assessed after single dose as well as after multiple dose administration; ? The site of application for the bioequivalence study should be in the same body area for both test and reference product; ? As patches are often highly variable drug products it is recommended to assess the intra-individual variability and, in particular, to determine the influence of biopharmaceutical performance on this variability by conducting a study with replicate design; ? If TDDS with different release mechanism (reservoir versus matrix) are compared a study using replicate design is required to investigate subject by formulation interaction; ? both products should demonstrate the same or less degree of local irritation, adhesiveness to the skin, phototoxicity (phototoxic potential), sensitization and similar systemic adverse events profile compared to the reference product; ? Bioequivalence is assessed using the same main characteristics and statistical procedures as for the prolonged release formulations
Biography
Relevant Topics
Top